^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CT032

    i
    Other names: CT032, CD19 redirected autologous cells, anti-CD19 chimeric antigen receptor T cell therapy, CAR-CD19 T cells
    Associations

    News

    Trials
    Company:
    CARsgen, Korea Kolmar
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Completed, CARsgen Therapeutics Co., Ltd. | Recruiting --> Completed | N=78 --> 20
    Trial completion • Enrollment change • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    cyclophosphamide • CT032
    over3years
    Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (clinicaltrials.gov)
    P=N/A, N=18, Active, not recruiting, Kang YU | Recruiting --> Active, not recruiting | N=48 --> 18 | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2019 --> Dec 2020
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18) • CD19 (CD19 Molecule) • GPC3 (Glypican 3)
    |
    CD19 positive • GPC3 positive
    |
    fludarabine IV • satricabtagene autoleucel (CT041) • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)